Subscribe

Dr. Chovatiya, Director of the Center for Eczema and Itch in the Department of Dermatology at Northwestern University Feinberg School of Medicine, reviews the emerging role of JAK inhibitors in dermatology and how these targeted therapies differ from traditional anti-inflammatory treatments. His discussion explains the underlying mechanisms of JAK inhibition and why these agents can offer meaningful benefits for certain patient populations.

Topics Covered

• The role of the JAK-STAT signaling pathway in inflammatory skin disease
• How JAK inhibitors work to selectively interrupt inflammatory signaling
• Differences between JAK inhibitors and other dermatologic therapies
• Potential advantages of JAK inhibitors for specific dermatologic conditions

Explore Related Resources

Early Use of Topical JAK Inhibitors
Checking in on Long-term Safety Data on JAK Inhibitors for Atopic Dermatitis